Again, the COVID thing is a giffin good.
I'm not one for just accepting coincidences. I'm currently reviewing the pipelines of Chinese companies that are doing business with CDY or that are running clinical trials in Australia for IP alignment.
Reasonably significant PEB royalties are now almost certain. A limiting factor could be the ability of PEB to turnover the test load.
cheers
Ann: Cellmid Signs Exclusive Agreement For Sars-Cov-2 Laboratory, page-29
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| AN1 (ASX) Chart |
Day chart unavailable